Patents by Inventor Mark B. Pepys

Mark B. Pepys has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combinations of SAP depleting agents and anti-SAP antibodies
    Patent number: 9192668
    Abstract: The invention describes the use of an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis, and the use of a compound which depletes serum amyloid P component from the circulation in combination with an antibody specific for serum amyloid P component.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: November 24, 2015
    Assignee: PENTRAXIN THERAPEUTICS LIMITED
    Inventor: Mark B. Pepys
  • Therapeutic agent
    Patent number: 8173694
    Abstract: Provided are agents and methods for use in depleting serum amyloid P component (SAP) from a patient in need thereof.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: May 8, 2012
    Assignee: Pentraxin Therapeutics Limited
    Inventor: Mark B. Pepys
  • Treatment and prevention of tissue damage
    Patent number: 8039222
    Abstract: A method for the treatment or prevention of tissue damage in a subject having an inflammatory and/or tissue damaging condition, which comprises administering to the subject an effective amount of a compound capable of inhibiting the binding of C-reactive protein (CRP) to an autologous or extrinsic ligand.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: October 18, 2011
    Assignee: Pentraxin Therapeutics Limited
    Inventor: Mark B. Pepys
  • Combinations of SAP depleting agents and anti-SAP antibodies
    Publication number: 20110166329
    Abstract: The invention describes the use of an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis, and the use of a compound which depletes serum amyloid P component from the circulation in combination with an antibody specific for serum amyloid P component.
    Type: Application
    Filed: October 29, 2010
    Publication date: July 7, 2011
    Inventor: Mark B. Pepys
  • Combinations of SAP depleting agents and anti-SAP antibodies
    Patent number: 7910106
    Abstract: The invention describes the use of an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis, and the use of a compound which depletes serum amyloid P component from the circulation in combination with an antibody specific for serum amyloid P component.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: March 22, 2011
    Assignee: Pentraxin Therapeutics Ltd.
    Inventor: Mark B. Pepys
  • THERAPEUTIC AGENT
    Publication number: 20100173969
    Abstract: Provided are agents and methods for use in depleting serum amyloid P component (SAP) from a patient in need thereof.
    Type: Application
    Filed: March 16, 2009
    Publication date: July 8, 2010
    Inventor: Mark B. Pepys
  • Compounds inhibiting the binding of sap for treating osteoarthritis
    Patent number: 7659299
    Abstract: Use of an agent capable of inhibiting SAP ligand binding activity or depleting SAP from the plasma of a subject for the production of a medicament for treatment or prevention of osteoarthritis in the subject.
    Type: Grant
    Filed: June 10, 2004
    Date of Patent: February 9, 2010
    Assignee: Pentraxin Therapeutics Limited
    Inventors: Mark B. Pepys, Philip Nigel Hawkins
  • Treatment and prevention of tissue damage
    Patent number: 7615543
    Abstract: An agent for use in medicine, which agent comprises a plurality of ligands covalently co-linked so as to form a complex with a plurality of C-reactive protein (CRP) molecules in the presence thereof, wherein (i) at least two of the ligands are the same or different and are capable of being bound by ligand binding sites present on the CRP molecules; or (ii) at least one of the ligands is capable of being bound by a ligand binding site present on a CRP molecule, and at least one other of the ligands is capable of being bound by a ligand binding site present on a serum amyloid P component (SAP) molecule.
    Type: Grant
    Filed: May 14, 2003
    Date of Patent: November 10, 2009
    Assignee: Pentraxin Therapeutics Limited
    Inventor: Mark B Pepys
  • USE
    Publication number: 20090191196
    Abstract: The invention describes the use of an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis, and the use of a compound which depletes serum amyloid P component from the circulation in combination with an antibody specific for serum amyloid P component.
    Type: Application
    Filed: December 30, 2008
    Publication date: July 30, 2009
    Inventor: Mark B. Pepys
  • TREATMENT AND PREVENTION OF TISSUE DAMAGE
    Publication number: 20090074745
    Abstract: A method for the treatment or prevention of tissue damage in a subject having an inflammatory and/or tissue damaging condition, which comprises administering to the subject an effective amount of a compound capable of inhibiting the binding of C-reactive protein (CRP) to an autologous or extrinsic ligand.
    Type: Application
    Filed: March 27, 2008
    Publication date: March 19, 2009
    Inventor: Mark B. PEPYS
  • Compounds Inhibiting the Binding of Sap for Treating Osteoarthritis
    Publication number: 20080249003
    Abstract: Use of an agent capable of inhibiting SAP ligand binding activity or depleting SAP from the plasma of a subject for the production of a medicament for treatment or prevention of osteoarthritis in the subject.
    Type: Application
    Filed: June 10, 2004
    Publication date: October 9, 2008
    Applicant: PENTRAXIN THERAPEUTICS LIMITED
    Inventors: Mark B. Pepys, Philip Nigel Hawkins
  • Treatment and prevention of tissue damage
    Patent number: 7390795
    Abstract: A method for the treatment or prevention of tissue damage in a subject having an inflammatory and/or tissue damaging condition, which comprises administering to the subject an effective amount of a compound capable of inhibiting the binding of C-reactive protein (CRP) to an autologous or extrinsic ligand.
    Type: Grant
    Filed: December 18, 2000
    Date of Patent: June 24, 2008
    Assignee: Pentraxin Therapeutics Limited
    Inventor: Mark B. Pepys
  • Treatment and prevention of tissue damage
    Publication number: 20030171251
    Abstract: A method for the treatment or prevention of tissue damage in a subject having an inflammatory and/or tissue damaging condition, which comprises administering to the subject an effective amount of a compound capable of inhibiting the binding of C-reactive protein (CRP) to an autologous or extrinsic ligand.
    Type: Application
    Filed: December 18, 2000
    Publication date: September 11, 2003
    Inventor: Mark B. Pepys
  • Screening assays to identify therapeutic agents for amyloidosis
    Patent number: 6126918
    Abstract: Therapeutical and diagnostic agents for amyloidosis comprise molecules that inhibit the binding of serum amyloid P component to amyloid fibrils or analogues or homologues of the amyloid binding site on serum amyloid P component. The resolution of the complete three dimensional structure of serum amyloid P component enables inhibitors, binding site analogues and homologues to be designed by computer-aided molecular modelling.
    Type: Grant
    Filed: August 22, 1996
    Date of Patent: October 3, 2000
    Assignee: Imperial College Innovations Limited
    Inventors: Mark B. Pepys, Thomas L. Blundell